GSK Lotronex: 20% Of Scripts Come From Physicians Outside Of Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
A survey completed by 36% of all Lotronex patients found they were very aware of the risks of the IBS therapy. FDA says it is too early to evaluate the overall effectiveness of the risk management program.